Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.14185
Abstract: Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in… read more here.
Keywords: imatinib sunitinib; sunitinib pazopanib; pazopanib flat; fixed dosing ... See more keywords